BioSpace News Archive

Companion diagnostics will be developed to identify patients with NSCLC that harbor ALK fusions and EGFR Exon20 insertion mutations to match patients with appropriate targeted therapies from Takeda

Recro (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for the development, formulation, regulatory support, manufacturing and packaging of oral solid dose drug products, today announced that Gerri Henwood, the Company’s President and Chief Executive Officer, will present at the Oppenheimer Fall Healthcare Life Sciences & Medtech Summit

The Foundation for the National Institutes of Health (FNIH) today bestowed its annual Trailblazer Prize for Clinician-Scientists to Michael Wilson , M.D., of the University of California San Francisco (UCSF). Dr. Wilson has received the Trailblazer Prize, along with a $10,000 honorarium, for pioneering a next-generat

Rafarma Pharmaceuticals, Inc. OTC:(RAFA) is pleased to announce the appointment of Ilia Shpurov as Chairman of the Board. Mr. Shpurov has a long history of technological developments, patents and entrepreneurial achievements in biotech. Most recently Mr. Shpurov purchased Kraspharma ( http://kraspharma.ru ) in 2008 and has built it into one of the top pharmaceutical companies in Russia. Mr. Shpurov also created the Pereslavsky Group

CURE Media Group, the industry-leading multimedia platform devoted to cancer updates and research that reaches more than 1 million patients, has selected Christie Santure, B.S.N., RN, OCN, the winner of the 2020 Extraordinary Healer® Award for Oncology Nursing, which honors exceptional nurses for their efforts in the oncology community.

The CMA agrees with Canada’s Premiers that additional federal funding is urgently needed to address the immense pressures on our health care system.

Document Security Systems, Inc. (“DSS” or the “Company”) (NYSE American: DSS), a multinational company operating businesses focusing on brand protection technology, blockchain security, direct marketing, healthcare, real estate, and securitized digital assets, today announced its wholly owned subsidiary Impact BioMedical, Inc. (“Impact BioMedical”), through its subsidiary Global BioLife, Inc. (“Global BioLife”)

Increasing the dose frequency of lanreotidefrom monthly to bi-monthly achieved a progression-free survival of 8.3 months in patients with progressive midgut neuroendocrine tumors (NETs) and 5.6 months in patients with progressive pancreatic NETs

Autolus Therapeutics plc announced new data highlighting progress on AUTO3, the company’s CAR T cell therapy being investigated in the ALEXANDER study, a Phase 1/2 clinical trial in relapsed/refractory diffuse large B cell lymphoma, during the European Society for Medical Oncology Virtual Congress 2020, beginning 18 September.

Beechtree Labs has chosen Curavit Clinical Research for a fully decentralized clinical trial to investigate a promising Covid-19 therapy.